Clinical Trials
By participating in clinical trials, you not only gain access to cutting-edge treatment & expert care, but you are participating in a potential medical breakthrough that could help many more people in the future.
Throughout the trial, you’ll be under the careful watch of leading physicians and research, ensuring your safety and well-being. If the medical treatment being tested in the clinical trial proves to be effective, you will be one of the first people to reap the benefits before it is released to the public.
Your participation today shapes tomorrow’s healthcare landscape.
Find a Clinical Trial
Filter Results By
- Postal Code
- Country
- Trial Status
-
Type of Trial
- Diagnosis
Sort by Trial name
28 Active Trials in 1161 Locations
Enter your Postal Code to find the nearest trial.
Sorry, that criteria does not currently fit any trials.
FeaturedThe EPPIK study will evaluate the investigational drug, sparsentan, for the treatment of selected rare kidney diseases. The investigational approach is to lower proteinuria levels with sparsentan and slow the loss of kidney function in children ages 2-17 with:
• IgA nephropathy (IgAN), also known as Berger’s disease
• IgA vasculitis (IgAV), also known as Henoch-Schönlein purpura
• Alport syndrome (AS)
See also the EPPIK Clinical Study for Children with FSGS and MCD.
FeaturedThe EPPIK study will evaluate the investigational drug, sparsentan, for the treatment of selected rare kidney diseases. The investigational approach is to lower proteinuria levels with sparsentan and slow the loss of kidney function in children ages 1-17 with:
• Focal segmental glomerulosclerosis (FSGS)
• Minimal change disease (MCD)
See also the EPPIK Clinical Study for Children with IgAN, IgAV, and Alport Syndrome.
The KIND study is testing the safety, efficacy, and pharmacokinetics of paricalcitol oral solution in participants of ages 0 to 9 years that have been diagnosed with Secondary Hyperparathyroidism (SHPT) associated with stage 5 Chronic Kidney Disease (CKD) receiving Peritoneal Dialysis (PD) or Hemodialysis (HD).
The ACTION3 Study will examine if the investigational medicine, DMX-200 (repagermanium), reduces the amount of proteinuria (protein in your urine) and slows the decline of kidney function, when taken in addition to a medicine called an angiotensin II receptor blocker (ARB) for 104 weeks.
The study is evaluating the safety and effectiveness of an investigational, targeted C3 inhibitor called pegcetacoplan in adults who have C3G or IC-MPGN recurrence after kidney transplant
The purpose of this study is to assess the efficacy and safety of twice weekly pegcetacoplan compared to placebo in patients with C3G or IC-MPGN, on the basis of a reduction in urinary protein levels.
This study is being done to see if the study drug, called BI 764198, may help people with FSGS. The study drug or a placebo will be taken as a capsule by mouth one (1) time every day for about 12 weeks.
JUSTICE is a single-center, double-blinded, randomized trial of baricitinib therapy for APOL1-associated FSGS or Hypertension Associated-CKD.
A study to learn if atrasentan is safe and works in people with IgA nephropathy who are taking an SGLT2 inhibitor.
The purpose of this study is to evaluate the safety and efficacy of BION-1301 in adults with IgA nephropathy.
Cure Glomerulonefropathy (CureGN) es un estudio observacional multicéntrico de cinco años de pacientes con enfermedad glomerular.
The Laboratory of Inherited Kidney Disease at Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, Massachusetts, directed by Dr. Martin Pollak, seeks to identify genes that underlie the development of FSGS and similar diseases.
The purpose of the I CAN Study is to evaluate the safety and effectiveness of ravulizumab compared with placebo to potentially help manage symptoms in adults who have IgAN
Liposorber LA-15 System is a blood processing system used outside of the body. This device removes certain lipoproteins (LDL/BDL) from the patient's blood. The Liposorber LA-15 System is used in patients diagnosed with focal segmental glomerulosclerosis (FSGS.) either before transplant, or after a kidney transplant in which there is a recurrence of FSGS.
The study is ongoing at pediatric sites.
Liposorber LA-15 System is a blood processing system used outside of the body. This device removes certain lipoproteins (LDL/BDL) from the patient's blood. The Liposorber LA-15 System is used in patients diagnosed with focal segmental glomerulosclerosis (FSGS.) either before transplant, or after a kidney transplant in which there is a recurrence of FSGS.
The IGNAZ Study is looking at the safety and effectiveness of Felzartamab in adults 18 to 80 years old with IgA nephropathy. Researchers want to compare different doses of Felzartamab to see which one might be better than taking no medicine at all.
El propósito de este estudio es recopilar datos de observación a largo plazo para ayudar a comprender la biología detrás del síndrome nefrótico.
This study seeks to explore taVNS as a potential, novel treatment for children with steroid resistant nephrotic syndrome (SRNS).
This study seeks to explore taVNS as a potential, novel treatment for children with frequently relapsing nephrotic syndrome (FRNS).
The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy.
Researchers from the University of Michigan and Northwestern University are studying people's experiences with swelling caused by Nephrotic Syndrome. Interviews with patients (child and adult) and parents of young children will be conducted. The information collected from the interviews will be used to develop a survey to use when testing new medications for Nephrotic Syndrome.
Please consider participating in a 1-hour long interview with the Prepare-NS research study to discuss children and adults experiences with swelling.
A Phase II, Multi-center, Open-Label Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of R3R01 in Alport Syndrome Patients with uncontrolled Proteinuria on ACE/ARB Inhibition, and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis.
This open-label, randomized multicenter study is to assess the efficacy, safety, and pharmacokinetics (PK)/pharmacodynamics (PD) of obinutuzumab compared with mycophenolate mofetil (MMF) in children and young adults (aged >= 2-25 years) with frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS).
The Rare Genomes Project aims to increase rare and undiagnosed families’ access to genomic research, empowering patients to directly accelerate the pace of rare disease diagnosis. This project was designed to be a direct partnership between researchers and patients, so we can better understand their conditions.
The TANGO study aims to create a large international network of centers to study glomerular disease (GN) recurrence after renal transplantation.
The purpose of the study it to measure the effectiveness of the study medication at improving kidney function to prevent damage in people who have IgAN.
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of VX-147 in participants aged 12 years and older with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin.
Welcome!
Welcome to the Kidney Health Gateway. Please answer some basic questions about you, or your loved one's, rare chronic kidney disease. We will use this information to provide you with a list of clinical trials and research opportunities in your area.
Thank You!
Please provide us with your contact information so that we can keep you updated as new research opportunities become available. We will never share or sell your information.
After entering your information, you will be asked 4 questions about your or your loved one's kidney disease.
Question 1
Please answer the next 4 questions on behalf of the person with kidney disease.